Case Studies of Resolving AAV Aggregation & Removing Empty Vectors

Time: 12:00 pm
day: Manufacturing - AM

Details:

• Case study one: aggregation occurring prior to the polishing chromatography step during final UFDF formulation and how this was resolved
• Case study two: novel purification to remove empty capsids – impurities potentially inducing an adverse immune response
• Outlining Fronter’s novel purification platform, removing empty capsids to <1% in the final drug substance

Speakers:

Robert Lu Robert Lu, VP of Technical Operations at Frontera Therapeutics, has 19 years’ experience in biologics drug development, including 8 years in the gene therapy field.